Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs
08 January 2014 - 1:33AM
Marketwired
Nutra Pharma Announces the First Shipments and Product Delivery to
MyNyloxin.com Independent Entrepreneurs
Nutra Pharma Is Announcing the Initial Shipments and Delivery of
the Company's Over-the-Counter (OTC) Pain Reliever, Nyloxin®, to
the MyNyloxin.com Independent Entrepreneurs (MIEs);
MyNyloxin Is the Exclusive Distributor of Nyloxin® in the
Network Marketing Channel
CORAL SPRINGS, FL--(Marketwired - Jan 7, 2014) - Nutra Pharma
Corp. (OTCQB: NPHC), a biotechnology company that is developing
treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple
Sclerosis (MS), is announcing that they have begun shipping the
initial product orders to MyNyloxin, a new company that has the
exclusive rights to market and distribute Nutra Pharma's
over-the-counter (OTC) pain reliever, Nyloxin®, in the Network
Marketing channel. Nutra Pharma previously announced the launch of
the MyNyloxin website that allows for product sales and information
as well as allowing distributors to sign up and view the Network
Marketing opportunity. Nutra Pharma will continue to market the
products through their retail and Direct Response distributors.
"Our Independent Entrepreneurs are excited to begin distributing
Nyloxin and sharing this opportunity," stated Dalton Johnson, CEO
of MyNyloxin.com. "MyNyloxin.com is comprised of a group of
professional marketers whom have come together on a mission to
spread awareness of Nyloxin," he continued. "By providing access to
a superior pain relief product that customers need and can trust
and by providing an innovative network marketing program which
offers a fair and balanced compensation plan for both the average
and ambitious MyNyloxin Independent Entrepreneur (MIE), we believe
that we will change lives for the better," he concluded.
In August 2013, Nutra Pharma announced the formation of
MyNyloxin.com, a new Multi-Level Marketing company that would act
as the exclusive Nyloxin® Distributor in the Network Marketing
channel. The pre-launch began in late December with the initial
orders shipping today. The launch is continuing and includes
webinars, internet, radio and television advertising.
"We're very happy with the relationship that we've created with
MyNyloxin," commented Rik J Deitsch, CEO of Nutra Pharma. "Network
Marketing allows for the rapid distribution of products directly to
the end-user and can rapidly provide product sales as well as
validity in the form of product user testimonials. We've already
received very favorable feedback from the MyNyloxin Distributors
and expect significant growth as the launch continues," he
concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically
proven to treat moderate to severe (Stage 2) chronic
pain. Nyloxin® is currently available in the United States as
an oral spray for treating back pain, neck aches, headaches, joint
pain, migraines, and neuralgia, and as a topical gel for treating
joint pain, neck pain, arthritis pain, and pain from repetitive
stress. In addition to its everyday strength formulation, Nyloxin®
is also offered in an extra strength formula for more advanced,
Stage 3, chronic pain. The Company recently announced the beginning
of marketing efforts by New Vitality for the Direct Response and
retail marketing of Nyloxin®. New Vitality's first Nyloxin®
television commercials are scheduled to begin shortly.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Additionally, the Company markets several drug products for sale
for the treatment of pain under the brands Cobroxin® and Nyloxin®.
For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.com.
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The delivery of product to MyNyloxin
Distributors should not be construed as an indication in any way
whatsoever of the future value of the Company's common stock or its
financial value. The Company's filings may be accessed at the SEC's
Edgar system at www.sec.gov. Statements made herein are as of
the date of this press release and should not be relied upon as of
any subsequent date. The Company cautions readers not to place
reliance on such statements. Unless otherwise required by
applicable law, we do not undertake, and we specifically disclaim
any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances
after the date of such statement.
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Dec 2023 to Dec 2024
